DUPHALAC (lactulose), hypoammonaemic osmotic laxative

Moderate clinical benefit for hepatic encephalopathy and constipation

• DUPHALAC has been granted a marketing authorisation for hepatic encephalopathy and for the symptomatic treatment of constipation.

• In cases of constipation, it should only be envisaged after lifestyle and dietary measures have failed and in combination with such measures.

• In cases of hepatic encephalopathy, it is recommended in cases of minimal or subclinical encephalopathy as a first-line symptomatic treatment in the acute phase, supplementing triggering factor management, and for preventing recurrences, with a non-optimal level of evidence.